This page is dedicated to the Sickle Cell Disease research study, one of 57 studies supported by the Boston Children’s Rare Disease Collaborative (CRDC). For more information about the CRDC, please visit our home page. Established in 2018, the CRDC supports pediatric rare disease research and provides families with genetic diagnoses that enable personalized treatments, including precision medicine and targeted therapies.
The Sickle Cell Disease research study, established at Boston Children's Hospital in 2019 and led by Drs. Carlo Brugnara and Vijay Sankaran, has enrolled over 800 patients and their families. The study aims to identify genetic causes of sickle cell disease and provide personalized medicine.